Trial Profile
A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 16 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
- 10 Jan 2008 Status changed from in progress to completed.
- 26 Jun 2007 Status changed from recruiting